Neurodegenerative disorders are defined by progressive nervous system dysfunction caused by neuronal loss in the brain and spinal cord. Despite substantial research efforts targeted at developing new disease-modifying therapies, no viable medication to slow neurodegenerative processes has yet to be discovered. As a result, changing current therapeutic and diagnostic research methodologies is becoming more urgent. The absence of adequate biomarkers is the most significant restriction in neurodegenerative disease research. It appears to be a tall order to find universal biomarkers capable of identifying individuals with neurodegenerative disorders, evaluating their response to therapy, and forecasting disease progression. Personalized medicine refers to the development of medicines and treatment processes that are best suited for a specific patient, taking both genetic and environmental factors into account. Its purpose is to combine new biotechnological advances in order to better understand disease pathogenesis and patient care. New genomic and proteomic discoveries have also aided the development of tailored therapy strategies.